Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infectious Diseases

Set Alert for Infectious Diseases

Ferring Makes Important Milestone For Microbiome With Rebyota Approval

The microbiome therapy won approval for preventing recurrence of Clostridioides difficile infections, but an analyst said the future could be in more targeted approaches.

Approvals Infectious Diseases

Sanofi Makes Big Strides In Eradicating Sleeping Sickness

The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.

Infectious Diseases Clinical Trials

Takeda Eyes Further Filings For Dengue Vaccine But Timings Unclear

With Qdenga’s US approval process moving ahead with the granting of a Priority Review and the dengue vaccine's first market launch, in Indonesia, expected early next year, Takeda has recently referred to plans to expand the product into other countries as well. But precise timings as yet remain unclear. 

Vaccines Infectious Diseases

Inovio Abandons Lassa, MERS Vaccines Shortly After Ending COVID-19 Booster Work

Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.

Business Strategies Clinical Trials

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

Gastrointestinal Market Access

GSK Phase II Win Offers Hope For TB Breakthrough

Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.

Infectious Diseases Clinical Trials

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

Clinical Trials Market Intelligence

GSK Reaches ‘First Base’ In Hep B Functional Cure But Has More To Prove

GSK is the first to raise the functional cure rate with its antisense drug, Phase II data suggest, but the company is looking for ways to boost responses across hepatitis B patients in its Phase III study.

Clinical Trials Companies

RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval

The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.

Approvals Infectious Diseases

How IVI Is Helping To Shape Korea’s Vaccine Ambitions

International Vaccine Institute Director General Jerome Kim talks to Scrip about the significance of South Korea's vaccine hub strategy and IVI's role, as well as the wider progress in the sector in the country.

South Korea Vaccines

Moderna Highlights Near-Term Non-COVID Readouts As Pandemic Vaccine Sales Drop

The company attributed lower-than-expected vaccine sales to supply issues, but it expects some significant read-outs over the next few months in respiratory infections and oncology.

Sales & Earnings Vaccines

GSK Hails Success For Novel Antibiotic – But Reaching $1bn Sales Will Be A Challenge

GSK is returning to its long heritage in antibiotics with a potential first-in-class drug that has just shown promise in urinary tract infection; hopes are that it can reach annual sales of  $1bn.

Companies Clinical Trials
See All
UsernamePublicRestriction

Register